By Admin at 25 Jan 2017
Women with advanced ovarian cancer may have a new option for treatment. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Rubraca (rucaparib), a poly ADP-ribose polymerase (PARP) inhibitor.
58
Current Gateway-funded clinical trials
150+
Clinical trials funded at leading institutions worldwide
$16.56
Funds one patient for one day at a Gateway-funded clinical trial
